Skip to content
S2387Senate2023-2024 Session

Investigate Drug Price Hikes

Official title

“Relates to investigating critical prescription drug pricing”

Sponsor Zellnor MyrieSD-20Affects Finance
Status
In Senate Committee
Insurance
Impact
8/10
Significant
Passage
0%

Bill progress

Step 2 of 7

In committee · Insurance

What's happening

This bill authorizes investigations and penalties for unjustified price increases of critical prescription drugs in New York.

Why it matters

  1. Targets price hikes exceeding inflation. The bill focuses on prescription drugs whose prices have risen in a year by more than the general cost of living, aiming to prevent price gouging on essential medications.

  2. Empowers state oversight. It gives the Superintendent of Insurance broad authority to investigate drug price increases, including the ability to subpoena witnesses and demand detailed information from manufacturers and sellers.

  3. Establishes strong penalties. Companies or individuals found to have unjustified price increases face significant civil penalties—potentially much higher than a flat fine—based on the damages caused or the profits gained from the price hikes.

  4. Defines “critical” drugs narrowly. Only drugs deemed necessary to prevent or treat life-threatening conditions are covered, focusing regulatory attention on medications where price spikes can have the most severe impact on public health.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • Department of Financial Services

    The bill would require the superintendent to obtain written explanations of critical prescription drug price increases under specified circumstances and authorize subpoenas and penalties for unjustified increases.

  • Drug manufacturers and sellers

    Those involved in critical prescription drug price increases could face investigations and civil penalties capped at the greatest of $5,000 per offense, twice aggregate damages or twice aggregate economic gain.

  • Patients with potentially fatal conditions

    The bill would subject pricing of drugs necessary to prevent or treat conditions in which death is possible or imminent to investigation for unjustified increases.

  • Company officers and employees

    Those subpoenaed in pricing investigations could be compelled to testify and produce records, with unjustified noncompliance carrying misdemeanor liability and potential civil penalties.

Headline styles

Investigate Drug Price Hikes

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Zellnor Myrie

Senator · Senate District 20

Chair, Elections

No co-sponsors yet.

History

  1. Referred to insurance
  2. Referred to insurance

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

2387

2023-2024 Regular Sessions

IN SENATE

January 20, 2023

Introduced by Sen. MYRIE -- read twice and ordered printed, and when printed to be committed to the Committee on Insurance

AN ACT to amend the insurance law, in relation to investigating critical prescription drug pricing

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. The insurance law is amended by adding a new section 346 to read as follows:

§ 346. Investigation by the superintendent with respect to critical prescription drugs. (a) Whenever it shall appear to the superintendent, either upon complaint or otherwise, that in the advertisement, purchase or sale within this state of any critical prescription drug, that the price of that critical prescription drug has increased over the course of any twelve months by more than the increase of the cost of living index for the list price of that critical prescription drug, or if it is suspected that any person, partnership, corporation, company, trust or association, or any agent or employee thereof has sold or offered for sale or is attempting to sell or is offering for sale any critical prescription drug for which the price of that drug has increased over the course of any twelve months by more than the increase of the cost of living index for the list price of that drug, or if the superintendent believes it is to the public interest to investigate, the superintendent shall require such person, partnership, corporation, company, trust or association, or any agent or employee thereof, to file with the department a statement in writing under oath or otherwise as to all the facts and circumstances concerning the price increase and for that purpose may prescribe forms upon which such statements shall be made.

(b) In addition to any other power granted by law, the superintendent, his or her deputy or other officer designated by the superintendent is empowered to subpoena witnesses, compel their attendance, examine them under oath and require the production of any books or papers which he or

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD04078-01-3

she deems relevant or material to the inquiry. Such power of subpoena and examination shall not abate or terminate by reason of any action or proceeding brought by the attorney general.

(c) No person shall be excused from attending such inquiry in pursuance to the mandates of a subpoena, or from producing a paper or book, or from being examined or required to answer a question on the ground of failure of tender or payment of a witness fee and/or mileage, unless at the time of such appearance or production, as the case may be, such witness makes demand for such payment as a condition precedent to the offering of testimony or production required by the subpoena and unless such payment is not thereupon made. The provisions for payment of witness fee and/or mileage shall not apply to any officer, director or person in the employ of any person, partnership, corporation, company, trust or association whose conduct or practices are being investigated.

(d) If a person subpoenaed to attend such inquiry fails to obey the command of a subpoena without reasonable cause, or if a person in attendance upon such inquiry shall without reasonable cause refuse to be sworn or to be examined or to answer a question or to produce a book or paper when ordered so to do by the officer conducting such inquiry, or if a person, partnership, corporation, company, trust or association fails to perform any act required by this section to be performed, he or she shall be guilty of a misdemeanor and shall be subject to a civil penalty as set forth in subsection (e) of this section.

(e) (1) If after an investigation authorized under this section the superintendent determines that the increase in the price of the critical prescription drug is unjustified, the superintendent may, after notice and a hearing, levy a civil penalty not to exceed the greater of:

(A) five thousand dollars for each offense;

(B) a multiple of two times the aggregate damages attributable to the offense; or

(C) a multiple of two times the aggregate economic gain attributable to the offense.

(2) If any person, partnership, corporation, company, trust or association, that fails to submit a written statement required by the superintendent under subsection (a) of this section or violates subsection (d) of this section, the superintendent may, after notice and a hearing, levy a civil penalty not to exceed to one thousand dollars per day that such failure continues.

(f) For the purposes of this section, a "critical prescription drug" shall be defined as one necessary to prevent or treat a disease or state in which death is possible or imminent.

§ 2. This act shall take effect immediately.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the insurance law, in relation to investigating critical prescription drug pricing

Purpose

To protect vulnerable populations from price increases for critical prescription drugs.

Summary of provisions

Section 1 amends the insurance law by adding a new section 346 which permits the superintendent to investigate any increase in a "critical prescription drug" as defined in the amendment that exceeds the consumer list price index during any preceding twelve month period. The super- intendent may require the submission of a statement in writing justify- ing the price increase and may also compel the attendance of witnesses to be examined under oath as well as require the production of any books or papers which the superintendent deems relevant to the investigation. A person's refusal to cooperate with the investigation will subject that person to civil and criminal penalties. This section also provides for civil penalties if, after investigation, the superintendent determines after notice and a hearing, that the increase in the price of the crit- ical prescription drug was unjustified.

Section 2 provides the effective date.

Justification

Anecdotal reports of significant price increases for prescription drugs is supported by the following data:

Overall spending on prescription drugs has risen tremendously since 1960.

The cost of the exact same drugs can differ by thousands depending on where in the country they are being purchased.

The price of insulin nearly doubled between 2012 and 2016.

In the first half of 2019, drug prices rose an average of 10.5%, or 5 times the rate of inflation.

From 2012 to 2017, brand name drugs rose on an average of 9.5 percent per year, leading researchers to conclude that drug prices are on pace to double every 7-8 years. (The drugs in this study included treatments for diabetes, smoking cessation, depression, cholesterol, pain, meno- pause, and erectile dysfunction.)

In a study of 49 common top-selling brand-name drugs, 78% of the drugs that have been available since 2012 have seen an increase in insurer and out-of-pocket costs by more than 50%, and 44% have more than doubled in price.

Nearly one in four Americans struggle to pay for their prescription drug prices and more than four in ten Americans in poor health struggle to afford their drugs. The poor and particularly the elderly are especially vulnerable to price increases. The inability to access reasonably priced drugs can be life-threatening. It is not unfair to require companies that manufacture and distribute critical prescription drugs to justify price increases that exceed the cost of living index. It is also not unfair to punish companies that engage in such practices that threaten the very lives of many Americans.

Legislative history

S320 of 2021-22: Referred to Insurance.

S7739 of 2019-20: Referred to Insurance.

Fiscal implications

To be determined.

Effective date

This act shall take effect immediately.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.